Publications by authors named "Ted Drogendijk"

Claim this Profile
L
Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
Marcus J Drake, Christopher Chapple, Roman Sokol, Matthias Oelke, Klaudia Traudtner, Ted Drogendijk

Eur Urol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of the Patient Perception of Intensity of Urgency Scale in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.
Susan D Mathias, Ross D Crosby, Jameel Nazir, Monique Klaver, Ted Drogendijk

Value Health· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptoms.
Christopher R Chapple, Marcus J Drake, Philip Van Kerrebroeck, Linda Cardozo, Ted Drogendijk

BJU Int· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial.
Philip van Kerrebroeck, Christopher Chapple, Ted Drogendijk, Monique Klaver, Roman Sokol

Eur Urol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II dose-ranging study of mirabegron in patients with overactive bladder.
Christopher R Chapple, Vladimir Dvorak, Pjotr Radziszewski, Philip Van Kerrebroeck, Jean Jacques Wyndaele, Ted Drogendijk

Int Urogynecol J· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE).
Linda Cardozo, Gerard Amarenco, Dmitry Pushkar, Jura Mikulas, Ted Drogendijk

BJU Int· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.
Vik Khullar, Gerard Amarenco, Javier C Angulo, Javier Cambronero, Kjetil Høye, Ted Drogendijk

Eur Urol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.
Christopher R Chapple, Steven A Kaplan, David Mitcheson, Jiri Klecka, Jana Cummings, Ted Drogendijk

Eur Urol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder.
Charlotte Eltink, Jennifer Lee, Marloes Schaddelee, Wenhui Zhang, Virginie Kerbusch, Ted Drogendijk

Int J Clin Pharmacol Ther· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
Linda Cardozo, Elke Hessdörfer, Rodolfo Milani, Pedro Arañó, Luc Dewilde, Ted Drogendijk

BJU Int· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis